Clinical Trial Update: Trial of Combination Tumor Treating Fields (TTF; Optune), Nivolumab Plus/Minus Ipilimumab for Recurrent Glioblastoma [Phase 2]

View source ↗

Summary

Phase 2 trial investigating combination Tumor Treating Fields (TTF/Optune) with nivolumab with/without ipilimumab for recurrent glioblastoma; trial terminated w…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Glioblastoma

Drugs mentioned

• Optune (Tumor Treating Fields) (Tumor Treating Fields)
• ipilimumab (ipilimumab)
• nivolumab (nivolumab)

Snippet

Sponsor: Baptist Health South Florida | Conditions: Recurrent Glioblastoma | Phase 2 | Status: TERMINATED | Results posted: 2023-02-02